Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial Post author:andrewkaretas Post published:July 15, 2026 Post category:CD70/Scientific Publications Continue ReadingAllogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
John Carroll and Dr. Zachary Roberts discuss interim ALPHA3 findings and the future potential of allogeneic CAR T in LBCL. Post author:andrewkaretas Post published:May 22, 2026 Post category:Perspectives Continue ReadingJohn Carroll and Dr. Zachary Roberts discuss interim ALPHA3 findings and the future potential of allogeneic CAR T in LBCL.
Cytokine-Driven Divergence Between Allogeneic CAR-T Platforms Post author:andrewkaretas Post published:May 13, 2026 Post category:PLATFORM/Scientific Publications Continue ReadingCytokine-Driven Divergence Between Allogeneic CAR-T Platforms
Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma Post author:andrewkaretas Post published:April 20, 2026 Post category:BCMA/Scientific Publications Continue ReadingPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma
Allogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-cell Lymphoma Patients Post author:andrewkaretas Post published:April 13, 2026 Post category:Perspectives Continue ReadingAllogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-cell Lymphoma Patients
Could a New Alternative to a Bespoke Treatment Change the Future of Cancer Care? Post author:andrewkaretas Post published:March 5, 2026 Post category:Perspectives Continue ReadingCould a New Alternative to a Bespoke Treatment Change the Future of Cancer Care?
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:January 23, 2026 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Post author:andrewkaretas Post published:January 21, 2026 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock.
First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study Post author:andrewkaretas Post published:December 31, 2025 Post category:CD19/Scientific Publications Continue ReadingFirst-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:December 22, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
